Acute respiratory failure associated with cladribine pneumonitis

Feenstra, John; Hickey, Bernadette; Blackwell, Eric

doi:10.1111/j.1445-5994.2004.00682.x

Cited by 12 publications

(11 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The tempo of onset (table 2) was usually acute or subacute (36 patients) [3,20,21,[23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39]. In six patients, the onset was hyperacute [17][18][19], and, in three patients, it was chronic [16,33,40].…”

Section: Tempo Of Onsetmentioning

confidence: 99%

“…The second peak, with 29 patients, occurred exactly on day 15, and eight additional cases occurred a few days before (days [8][9][10][11][12][13][14][15] or after (days 15-21) this second peak. Thus 37 patients experienced delayed-onset forms [3,[20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39]. Finally, the third peak reflected late-onset forms, occurring 1-3 months after the last infusion in three patients [16,33,40].…”

Section: Time-to-onset Datamentioning

confidence: 99%

See 1 more Smart Citation

Rituximab-induced lung disease: a systematic literature review

Lioté¹,

Lioté²,

Séroussi³

et al. 2009

Eur Respir J

156

120

View full text Add to dashboard Cite

The anti-CD20 antibody rituximab has been reported to induce a heterogeneous spectrum of lung disorders. The aim of the present study was to critically review data on the clinical presentations, causality assessments and management strategies of lung diseases possibly related to rituximab.A systematic literature review was performed on English-language reports in PubMed until September 2008.Cases of lung diseases ascribed to rituximab (n545) were identified, with three time-to-onset patterns. The most common presentation was acute/subacute hypoxaemic organising pneumonia (n537), starting 2 weeks after the last infusion (often around the fourth cycle) and resolving, in most cases, provided glucocorticoid therapy was given early. Acute respiratory distress syndrome occurred in five patients, within a few hours and usually after the first infusion. In the remaining three patients, macronodular organising pneumonia developed insidiously long after rituximab therapy and responded to steroids. Eight patients died. Based on time to onset, symptoms, and responses to discontinuation and rechallenge with rituximab and other drugs, 13 cases were highly compatible and 32 compatible with rituximab-induced lung disease.Knowledge of these presentations of rituximab-induced lung disease should prove helpful for diagnosis and causality assessment purposes. Time-to-onset data, suggesting different pathogenic mechanisms, support closer clinical and perhaps radiological monitoring between infusions, particularly in patients with a history of reversible respiratory symptoms.

show abstract

Section: Tempo Of Onsetmentioning

confidence: 99%

Section: Time-to-onset Datamentioning

confidence: 99%

Rituximab-induced lung disease: a systematic literature review

Lioté¹,

Lioté²,

Séroussi³

et al. 2009

Eur Respir J

156

120

View full text Add to dashboard Cite

show abstract

“…Among reported cases in which pathology reports were available, the predominant finding was BOOP [8, 10, 14–19]. Interstitial pneumonia/pneumonitis with or without interstitial fibrosis was the second most common diagnosis [1, 10, 20–22].…”

Section: Discussionmentioning

confidence: 99%

Rituximab-Induced Bronchiolitis Obliterans Organizing Pneumonia

Ergin

Fong

Daw

2012

Case Reports in Medicine

View full text Add to dashboard Cite

Rituximab-induced lung disease (R-ILD) is a rare entity that should be considered in patients treated with rituximab who present with dyspnea, fever, and cough, but no clear evidence of infection. A variety of pathologic findings have been described in this setting. Bronchiolitis obliterans organizing pneumonia (BOOP) is the most common clinicopathologic diagnosis, followed by interstitial pneumonitis, acute respiratory distress syndrome (ARDS), and hypersensitivity pneumonitis. Prompt diagnosis and treatment with corticosteroids are essential as discussed by Wagner et al. (2007). Here we present a case of an 82-year-old man who was treated with rituximab for recurrent marginal zone lymphoma. After the first infusion of rituximab, he reported fever, chills, and dyspnea. On computed tomography imaging, he was found to have bilateral patchy infiltrates, consistent with BOOP on biopsy. In our patient, BOOP was caused by single-agent rituximab, in the first week after the first infusion of rituximab. We reviewed the relevant literature to clarify the different presentations and characteristics of R-ILD and raise awareness of this relatively overlooked entity.

show abstract

“…Elle n'est pas essentielle au diagnostic, car il n'y a pas d'aspect histologique spécifique, qu'un même médicament peut être associé à plusieurs aspects histologiques [27] bien décrit avec l'amiodarone [55], parfois même au sein du même pré-lèvement [41,56]. Elle peut montrer un aspect de dommage alvéolaire diffus [41], de pneumonie interstitielle non spéci-fique, de pneumonie organisée [42] et fibrineuse aiguë rapportée avec l'amiodarone [57,58], de pneumonie interstitielle desquamative, de pneumonie granulomateuse non nécrosante [59], ou d'une fibrose associée à une atteinte inflammatoire sans description précise.…”

Section: Histologie Pulmonaireunclassified

Toxicité pulmonaire des médicaments : ce que le réanimateur doit connaître ?

Parrot

Gibelin

Issoufaly

et al. 2018

Méd. Intensive Réa.

View full text Add to dashboard Cite

Résumé Le diagnostic d'insuffisance respiratoire aiguë d'origine médicamenteuse est un véritable défi. Les traitements à l'origine d'une toxicité pulmonaire sont très nombreux. Les nouveaux traitements, notamment en oncohématologie (thé-rapie ciblée, immunothérapie), ne sont pas en reste. L'expression clinique très hétérogène est sous-tendue par des mécanis-mes lésionnels très différents. Après avoir écarté une infection ou un oedème pulmonaire, il faut savoir évoquer une pneumopathie médicamenteuse. La réalisation d'un scanner thoracique et d'une fibroscopie bronchique avec lavage bronchoalvéolaire peut être utile pour exclure une pathologie infectieuse et suggérer une pathologie médicamenteuse. Le traitement est l'arrêt du médicament et repose fréquemment dans ces formes graves sur une corticothérapie. Mots clés Détresse respiratoire · Pneumopathie médicamenteuse · Toxicité pulmonaireAbstract Acute respiratory failure related to drug toxicity is challenging. Several drugs, also including targeted therapy and immunotherapy, have been reported to induce lung toxicity. Clinical and pathological presentations are heterogeneous suggesting different toxicity pulmonary mechanisms. Infection or pulmonary edema should be ruled out, and then drug-induced pneumonitis diagnosis should be considered. CT scan and bronchoscopy with bronchoalveolar lavage are helpful for the disease diagnosis. Due to the severity, the identified drug should be stopped and more frequently steroids should be started.

show abstract

Acute respiratory failure associated with cladribine pneumonitis

Cited by 12 publications

References 4 publications

Rituximab-induced lung disease: a systematic literature review

Rituximab-induced lung disease: a systematic literature review

Rituximab-Induced Bronchiolitis Obliterans Organizing Pneumonia

Toxicité pulmonaire des médicaments : ce que le réanimateur doit connaître ?

Contact Info

Product

Resources

About